Mind Medicine Inc’s recently made public that its Chief Executive Officer Barrow Robert unloaded Company’s shares for reported $0.14 million on Mar 25 ’25. In the deal valued at $6.74 per share,21,208 shares were sold. As a result of this transaction, Barrow Robert now holds 856,556 shares worth roughly $5.4 million.
Then, Karlin Daniel sold 6,836 shares, generating $46,075 in total proceeds. Upon selling the shares at $6.74, the Chief Medical Officer now owns 446,177 shares.
Before that, Sullivan Mark sold 6,576 shares. Mind Medicine Inc shares valued at $44,322 were divested by the Chief Legal Officer at a price of $6.74 per share. As a result of the transaction, Sullivan Mark now holds 316,621 shares, worth roughly $2.0 million.
Evercore ISI initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on January 28, 2025; the price target was $23. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. ROTH MKM started covering the stock on July 24, 2024. It rated MNMD as “a Buy”.
Price Performance Review of MNMD
On Tuesday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock fall -3.66% to $6.31. Over the last five days, the stock has gained 0.16%. Mind Medicine Inc shares have fallen nearly -9.34% since the year began. Nevertheless, the stocks have fallen -33.72% over the past one year. While a 52-week high of $10.44 was reached on 02/14/25, a 52-week low of $4.70 was recorded on 04/09/25. SMA at 50 days reached $6.19, while 200 days put it at $6.83.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 6.20, which if violated will result in even more drops to 6.09. On the upside, there is a resistance level at 6.50. A further resistance level may holdings at 6.69. The Relative Strength Index (RSI) on the 14-day chart is 51.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 42.11%. Stochastics %K at 75.39% indicates the stock is a holding.
The most recent change occurred on May 29, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $27 price target.
